🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

"Approximately 5%of annual cancer diagnoses or 100,000 cancers were projected to result from [U.S.] CT utilization in 2023. "jamanetwork.com/journals/jamai…

Interested in myeloid cell anti-tumor immunity? I’ll be presenting at National Cancer Institute Rising Scholars Seminar Series on 17 Apr our work on Fc-optimized CD40 Agonistic Antibody and TLS formation and induction of Systemic Antitumor Immunity cassyni.com/events/Eg84FXZ…

I remember when this proposal was in draft mode at AACR #MBCO workshop congrats @dr_cjackson

Tumor infiltrating clonal hematopoiesis associated with poor outcomes in solid tumors. Wonder if this is how IL1B inhibition seemed to improve survival from cancer in CANTOS… nejm.org/doi/full/10.10…

If you are in the NY area and looking for updates in #GU, join us in NYC on 4/30 for OncLive.com #Stateofthescience summit. Free for healthcare professionals to register here! shorturl.at/uTCUA

⬇️ Can’t think of a more innovative, impactful, and incredible example of Team Science! Congrats to the Memorial Sloan Kettering Cancer Center IMPACT team! 👏👏 Michael Berger David B. Solit, MD Marc Ladanyi + many more team members! #AACR25 AACR

New in NEJM and #AACR2025: Our Early-stage MMR-d neoadj I/O trial (led by Andrea Cercek & Luis Diaz) •100 % cCR in 49 rectal pts •65 % cCR across 10 other cancers (n=54) •Safe + all non-CR/recurs salvaged. =Use IO in NA for MMR-d tumors! nejm.org/doi/full/10.10…

Excited for tomorrow! #AACR2025

Juan C Osorio MD presents his beautiful translational work on CD40 agonist 2141-V11. #TLS formation implicated response in #bladdercancer. ➡️Keep Dr. Osorio on your radar. He is a 🌟. He will be starting his own lab as an independent investigator soon! #K08 #AACR25 #AACRMBCO

Join thoracic medical oncologist Adam J. Schoenfeld for his poster session titled “OBX-115 TIL from non-small cell lung cancer (NSCLC) are enriched for putative tumor-reactive, stem-like T cells with enhanced tumor cytotoxicity: Results from multimodal phenotyping analysis” today

1/2 Here’s our updated advanced urothelial cancer Uromigos Score (20 experts from around the world). It’s designed to give clinical strength/granularity to guidlines (which often give a list of equal options). Thanks to those that took part (on the 2nd slide). As things change,

🚨 New research from MSK and Weill Cornell Medicine shows that BCG, the first FDA-approved cancer #immunotherapy, doesn't just act locally in the bladder. It travels to the bone marrow, where it reprograms and amplifies immune stem cells, boosting the body’s ability to fight cancer more

Very proud of Michal Sternschuss for her work outlining post EV + P therapy. See Uromigos rapidly summarizing her data #ASCO2025

#ASCO25: We will present Phase Ill data, also published in NEJM, for metastatic SCLC, offering a new option for this aggressive cancer, leveraging the use of T-cell engagers. nejm.org/doi/full/10.10…

A blog post on CHALLENGE and why you should be prescribing exercise today #ASCO25 A 🧵 with some resources for you:

The most robust data post EVP in M1 bladder cancer by Michal Sternschuss MSKCC Carboplatin/gem was the commonest regimen #ASCO25 OncoAlert Results showed ⬆️ RRs than expected (50%) PFS =4.5 months & OS =11 months are good. 1st line gem/carbo OS was ~10 months previously?

NCI congressional justification released. $1.26 BILLION cut in research grants and a 15% indirect rate.

Quality of Informed Consent via #Telemedicine Compared With In-Person for Clinical #Cancer Research. ascopubs.org/doi/10.1200/OP… ASCO Journal of Clinical Oncology JCO Oncology Practice #CancerResearch #Telehealth Memorial Sloan Kettering Cancer Center Andrew Vickers